Bafna PharmaceuticalsNSE:BAFNAPH +5.00%60 Days Payable is 96.00 as of Mar. 2026, which is 16% below its 10-year median of 114.17. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 920 Drug Manufacturers companies, Bafna Pharmaceuticals ranks better than 58.48% on this metric.
The historical rank and industry rank for Bafna Pharmaceuticals's Days Payable or its related term are showing as below:
NSE:BAFNAPH'
s Days Payable Range Over the Past 10 Years
Min: 82.2 Med: 114.17 Max: 359.88
Current: 104.77
During the past 13 years, Bafna Pharmaceuticals's highest Days Payable was 359.88. The lowest was 82.20. And the median was 114.17.
NSE:BAFNAPH's Days Payable is ranked better than 58.48% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:BAFNAPH: 104.77
Bafna Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bafna Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Days Payable of 96.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bafna Pharmaceuticals and its competitors. This is 16% below median its historical median of 114.17. Over the past decade, Bafna Pharmaceuticals' Days Payable has ranged from 82.20 to 359.88. According to the industry distribution chart, Bafna Pharmaceuticals ranks #382 out of 920 companies in the Drug Manufacturers industry, placing it in the top 41.5%.
Is Bafna Pharmaceuticals' Days Payable too high?
Bafna Pharmaceuticals' current Days Payable of 96.00 is 16% below median its 10-year median of 114.17. Over the past 10 years, this metric has ranged from a low of 82.20 to a high of 359.88. The Drug Manufacturers industry median Days Payable is 90.84. Bafna Pharmaceuticals' value of 96.00 is 5.7% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #382 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #382 out of 920 companies for Days Payable. This puts Bafna Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 90.84. Bafna Pharmaceuticals' value of 96.00 is 5.7% above this benchmark. Historically, Bafna Pharmaceuticals' own Days Payable has ranged from 82.20 to 359.88 over the past decade. While the company's 10-year median is 114.17 vs. the industry median of 90.84, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Days Payable of 96.00 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Days Payable is 96.00, which is 16% below median its own 10-year median of 114.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.79, compared to a current price of ₹194.68 — trading 112.1% above its estimated fair value. The current Days Payable is 96.00, which is 16% below median its 10-year median of 114.17 and 5.7% above the Drug Manufacturers industry median of 90.84. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Days Payable is 96.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 112.1% above its estimated GF Value™ of ₹91.79.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Days Payable: 96.00 (16% below median its 10-year median of 114.17)
GF Value™: ₹91.79 vs. price of ₹194.68 (112.1% above fair value)
Industry Position: 5.7% above the Drug Manufacturers median (#382 of 920)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
